Literature DB >> 10873597

Kaposi's sarcoma cells of different etiologic origins respond to HIV-Tat through the Flk-1/KDR (VEGFR-2): relevance in AIDS-KS pathology.

M Morini1, R Benelli, D Giunciuglio, S Carlone, G Arena, D M Noonan, A Albini.   

Abstract

Kaposi's sarcoma (KS) is an hyperplastic lesion whose main histological features are typical spindle shaped cells with a mixed endothelial-mesenchymal-macrophage phenotype, an intense vascularization and an inflammatory infiltrate. The etiology of KS appears to be linked to activation of a latent HHV8 infection. Sporadic and iatrogenic KS are slow progressing lesions that can undergo spontaneous regression. In contrast, KS, which is frequently associated with HIV infection, is found in a highly aggressive form in AIDS patients. The HIV-1 Tat has been shown to activate the VEGF receptor KDR in endothelial and KS spindle cells, suggesting this HIV protein could contribute to KS pathogenesis. We used primary 'reactive' KS cell culture from sporadic and epidemic KS, and an immortal KS-line (KS-Imm) isolated in our laboratory from a iatrogenic KS lesion, to verify if Tat-induced cell signaling is able to mediate cellular responses. We demonstrate that KS cells migrated in response to Tat and that VEGF is able to compete with the Tat chemotactic activity towards these cells. A function-blocking anti-KDR antibody was able to abrogate both VEGF and Tat-induced KS chemotactic response, indicating a direct involvement of this receptor. Our data show that HIV-Tat can also activate KS cells derived from sporadic or iatrogenic lesions, suggesting that in AIDS patients Tat could cooperate with VEGF in activation of KDS on KS precursor spindle and endothelial cells, and contribute to the aggressiveness of AIDS-KS lesions. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873597     DOI: 10.1006/bbrc.2000.2941

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  The NADPH oxidase NOX4 promotes the directed migration of endothelial cells by stabilizing vascular endothelial growth factor receptor 2 protein.

Authors:  Kei Miyano; Shuichiro Okamoto; Akira Yamauchi; Chikage Kawai; Mizuho Kajikawa; Takuya Kiyohara; Minoru Tamura; Masahiko Taura; Futoshi Kuribayashi
Journal:  J Biol Chem       Date:  2020-07-02       Impact factor: 5.157

Review 2.  Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma.

Authors:  Giovanni Barillari; Barbara Ensoli
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

3.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

Authors:  Vera Eremina; Manish Sood; Jody Haigh; András Nagy; Ginette Lajoie; Napoleone Ferrara; Hans-Peter Gerber; Yamato Kikkawa; Jeffrey H Miner; Susan E Quaggin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

4.  Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat.

Authors:  Teresa G D'Aversa; Karl O A Yu; Joan W Berman
Journal:  J Neurovirol       Date:  2004-04       Impact factor: 2.643

5.  Human immunodeficiency virus type 1 tat-mediated cytotoxicity of human brain microvascular endothelial cells.

Authors:  Naveed Ahmed Khan; Francescopaolo Di Cello; Avi Nath; Kwang Sik Kim
Journal:  J Neurovirol       Date:  2003-12       Impact factor: 2.643

6.  HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas.

Authors:  J Nyagol; G De Falco; S Lazzi; A Luzzi; G Cerino; S Shaheen; N Palummo; C Bellan; D Spina; L Leoncini
Journal:  J Hematop       Date:  2008-04-16       Impact factor: 0.196

7.  HIV-1 Tat protein induces the production of IDO in human monocyte derived-dendritic cells through a direct mechanism: effect on T cells proliferation.

Authors:  Rémi Planès; Elmostafa Bahraoui
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.